Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Articles
Articles
Use of High-Cost Tests for Lung Cancer Surveillance Rising
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
June 2013, Vol 4, No 5
The use of costly diagnostic imaging of uncertain value is increasing rapidly for patients with localized non–small-cell lung cancer (NSCLC), according to data from the Surveillance, Epidemiology and End Results (SEER)-Medicare database.
Read More
Medicare Committee Gives Thumbs Down to New Genetic Tests for Cancer
By
Ross D. Margulies, JD, MPH
;
Jayson Slotnik, JD, MPH
Health Policy
,
Policies & Guidelines
June 2013, Vol 4, No 5
Mr Margulies is an Associate, Foley Hoag, LLP, and Mr Slotnik is a Partner, Health Policy Strategies, LLC, Washington, DC
Read More
Immunotherapies Take Center Stage in Melanoma
By
Audrey Andrews
ASCO Annual Meeting
,
ASCO
June 2013, Vol 4, No 5
Chicago, IL—Data continue to build for the application of immunotherapy for patients with metastatic melanoma. At the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO), several sessions were devoted to recent advances in melanoma, focusing on new ways to boost the activity of current therapies, introducing a new class of immunotherapy in development, and a new form of immunotherapy—an oncolytic vaccine.
Read More
Prostate Cancer Risk Doubles in Men with Lynch Syndrome
In the Literature
June 2013, Vol 4, No 5
Lynch syndrome (LS) is an inherited syndrome of predisposition to cancer with an increased risk for colorectal cancer ranging from 30% to 80%. Prostate cancer has been described as a component tumor of LS, but the lifetime risk of prostate cancer in patients with LS has not been quantified because of inherent difficulties. In a new analysis, researchers have used genetic data to define the risk of prostate cancer in men with LS (Raymond VM, et al.
J Clin Oncol
. 2013;31:1713-1718).
Read More
Crizotinib Superior to Standard Chemotherapy in Patients with ALK-Positive Lung Cancer
In the Literature
June 2013, Vol 4, No 5
Read More
Rituximab Maintenance Prolongs PFS in Patients with Relapsed Lymphoma
In the Literature
June 2013, Vol 4, No 5
Read More
Bevacizumab an Effective New Treatment Option for Relapsed Cervical Cancer
By
Wayne Kuznar
ASCO Annual Meeting
,
ASCO
June 2013, Vol 4, No 5
Chicago, IL—Adding bevacizumab (Avastin) to standard chemotherapy improves overall survival (OS) in women with metastatic or relapsed cervical cancer, representing the first instance in which a targeted therapy has significantly prolonged OS in this patient population.
Read More
FDA Expected to Approve Surrogate End Point for Neoadjuvant Breast Cancer Trials
By
Caroline Helwick
ASCO Annual Meeting
,
ASCO
June 2013, Vol 4, No 5
Chicago, IL—For years, the cancer research community has pushed for the use of surrogate end points in clinical trials as a means of hastening the drug approval process. At the 2013 American Society of Clinical Oncology (ASCO) annual meeting, the speakers discussed the potential implications for researchers, providers, and patients.
Read More
The Changing Landscape of Oncology
June 2013, Vol 4, No 5
At the Third Annual Conference of the Association for Value-Based Cancer Care, 2 oncologists representing opposite corners of the oncology care landscape discussed the current trends in the delivery of patient care, and the challenges that are facing oncologists.
Read More
Oncology Practices Need to Transform the Way They Deliver Cancer Care
June 2013, Vol 4, No 5
Oncology practices need to transform the way they deliver cancer care, said John D. Sprandio, MD, FACP, Chief of Oncology at Delaware County Memorial Hospital in Drexel Hill, PA, and Medical Director of ION Solutions.
Read More
Page 258 of 329
255
256
257
258
259
260
261
Top Trending Articles
1.
Immunotherapy Helps Navy Veteran Beat Stage 4 Lung Cancer
2.
HOPA Highlights: What's New in 2025?
3.
Peer Navigation Intervention Aims to Boost Childhood Cancer Clinical Trial Participation
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma